Julie Frappier
Health Economist

Tel. : 514.945.9795
Mail : info@data4actions.com

Who we are?

Active in the health economics field since the late 80s, with more than 25 years of health economics consulting experience in the North American and European pharmaceutical & healthcare technologies industries, Julie has established a reputation for excellence in the planning and implementation of pharmacoeconomics and outcome research studies that meet and exceed client expectations.

In her work on more than 250 health economic projects, Julie has maintained a focus on economic piggyback studies, economic risk management trials, price justification, market identification and justification and disease management. Julie has substantially contributed to Quebec and Canada’s growing R&D-oriented healthcare industries by providing her unique expertise to key organizations.

Julie has acted as advisor in health economic studies for the Quebec Hospital Association (AHQ) and filled the role of chairperson to the 1st AHQ pharmacoeconomics workshop in 1993. Julie has also been a speaker at many conferences.

Julie has been interviewed and quoted by the Pharmacoeconomics Prix Galien supplement, has been a member of the DIA’s Canadian & North American Programme Steering Committee and has contributed to the Rotation program at Sandoz (clinical, scientific affairs and marketing departments).

La Presse asked her to write a full-page article in the Editorial section regarding drug development costs (April 2002). She has published many publications and posters with the Montréal Economic Institute, Québec Pharmacie, the Journal of Medical Economics, the Drug Information Association (DIA) and others.

Julie has furthermore maintained a close and lasting relationship with the academic community. She has aided doctoral students as thesis pragmatic expert and has been a lecturer for Master’s students at the University of Montreal’s economic department. From 2002-2006, Julie taught health economics at the MBA (MBA 8B1B) level for the group specialized in bio-industries. She has also co-authored a book chapter about health economics of depression (Thérapeutique Psychiatrique, Éd. Hermann, 1995).

Why Health Economics?

Attention regarding the relationship between costs and efficacy of life sciences is relatively recent. The urgent need for health outcomes research was highlighted in the early 80s. Considering the spiraling escalating rise in healthcare costs, the demand for a more rational allocations of life science products and services has never been more crucial. For instance, 4 decades ago, physicians only had to choose among available interventions by referring to clinical endpoints (safety and efficacy); sales representatives would inform physicians on a given product and expect them to prescribe and adopt it.

Whether they like it or not, healthcare professionals must now also examine costs, as governments, hospitalsand private third party payers are striving to optimize care to patients subject to their existing budgets. A product has no longer to be safe and efficacious; it must also be efficient. On the other side, the struggle of generating a positive return on investment for healthcare products and services has neverbeen more challenging.

Since healthcare professionals, payers, policymakersand producers of healthcare technologies are often faced with the difficult task of assessing the value of a new product or justifying the addition of a new clinical service, either costs, effectiveness or market size is often the only factor considered.

No matter how wealthy the economy of a nation is and how strong its economic system is, there will never be unlimited resources to satisfy the society’s needs. Policymakers, consumers, producers of healthcare technologies, payers and all other individuals and groups involved in the economy must make hard choices about how to allocate resources.

When individuals choose to purchase a medication, they cannot use the same money to purchase something else. Similarly, when governmental policymakers authorize expenditures on medications, there are competing demands that cannot be fulfilled. This idea can be generalized into one of the most important concepts guiding economics: the opportunity cost. Economics, whether applied to life sciences or to any other goods and services, is not about reducing costs (cost containment strategies), it is about maximizing their net outcomes subject to society’s given available resources.

Most of the actual interventions seek to control costs rather than to improve the efficiency of resource allocation. Sound economic studies seek to improve the methodological issues and principles of clinico-economic evaluations.

Finally, it is not important for healthcare actors to be able to perform health economic studies but it is essential for them to understand how and why these analyses are performed and thus, why certain recommendations were outlined. Health care actors should remember that the national Health Care system is seeking to deliver the most efficient healthcare, not the cheapest one.

Spending is not the enemy – wasting is!

Why Health Economics with Data 4 Actions?

Data 4 Actions is a company specialized in behavioral health economics. Our strength is that we master microeconomic notions that can translate into a powerful research protocol that will have the ability to influence end-users about the economic relevance of a given product or service.

At Data 4 Actions, we go beyond writing a report with rigorous and sound data. We strive to transform data into a meaningful story that informs the 5Ps of the economic relevance ofa given product or service and thus, justify the need to take action.

At Data 4 Actions, because of our background,we apply underlying behavioral microeconomics notions to our projects. This enables topromote powerful and meaningful reports that will leverage actionable strategies that will influence healthcare actors - 5Ps -; rather than opting for strategies dealing primarily with cost-containment that will ultimately lead to wastage.

How do we build each customized stories? We build them, over and above our experience, expertise and dedication to success for each of the 5Ps, through:

  • an adapted multi-disciplinary team
  • an adapted pragmatic team to validate the research hypotheses and study rationale
    • Regardless of the quality of the research, if the research hypothesis and study rationale is sub-optimal it is most likely that results will become sub-optimal since we know the adage: “Garbage in… garbage out”.
  • By transferring key economic notions into a relevant data collection form
  • Using appropriate check-lists to assure the soundness of the method and the publication and assuring transparent and conservative assumptions
  • By proposing the most optimal story and justifying the underlying assumptions where the 5Pswill all be in a Pareto optimal situation: a win-win

The GLPS of the 5PS


Julie loves to share her passion and experience about health economics. Hence, she was invited to be a spokesperson in many events. These events mostly consist of:


Health Canada : Health Economic Training

Strategic Pricing Symposium (Montreal)

Oswestry Cartilage Meeting (Oswestry, UK)

BioMedex (Montreal)

Montreal Economic Institute (Montréal)

Université Laval – Presentation to the infectious disorder department (Québec)

Drug Information Association (San Diego, USA)

Wound Care Congress (Montreal)

World Vaccine (Montreal)

Annual symposium - Association des hôpitaux du Québec (Montreal)

Les médicaments en l’an 2000, Virage 98 (Montreal)

BioAlliance Canada-Maroc (Montreal)


Academic Environment

UQAM (lecturer) – MBA department

UQAM - Guest speaker

Université Laval – Guest speaker

Université de Montréal – Guest speaker

Pragmatic Experience

Over the last 25 years, Julie built “health economic stories”. Please find hereunder a list of the impact of some of her projects.

Justify the economic efficiency of healthcare technologies (Canada, USA, Europe)

See the impact
The impact :

Through the economic strategies that were designed in collaboration with the client, many products were listed for reimbursement; even for products that were highly challenging due to their significant premium price to competition.

Economic piggy-back to a clinical trial

See the impact
The impact :

Collaborated to the economic strategy and implantation of international clinical trials, implicating up to 7 countries; for phase I to phase IV trials, secondary or primary to a clinical trial strategy/design.

Price justification

See the impact
The impact :

Through various complementary rigorous economic assesments, managed to influence a top 5 worldwide pharmaceutical to adapt an independent Canadian strategy (significant price reduction of the medication)

Ethics committee

See the impact
The impact :

100% of the projects that were submited were approved by the ethics committees (hospital/private)

Market justification

See the impact
The impact :

Through the results of Willingness-to-pay trials results generated significant impact on the redesign of the strategic business plan

Collaborated with many small biopharma’s to assess the economic market risk/value of their various indications; frequent collaboration to assist them in the complex task of go/no analyses through economic data.

Patient/Disease management

See the impact
The impact :

Collaborated to strategies and implementation of large multi-center trials; implicating more than 3000 patients and 500 physicians.

Health Policy

See the impact
The impact :

Project leader for l’Institut Économique de Montréal to determine the feasibility and success factors for enabling nurses and specialized physicians to offer their services in the private sector, over and above their actual scope in the public sector.

Go/No Go – Venture capital firm

See the impact
The impact :

Collaborated with venture capital firms to assess the economic risks of investing healthcare technology firms (go/no go).

Collaborated with healthcare technology firms to strengthen their business plan (through economic data) to optimize investment funds from venture capital firms and pharmaceuticals.

Indications and types of projects

Over the last 25 years, Julie has performed projects in various indications and adapting various methodologies. Please find hereunder a list of her various experience over the last 25 years.



Alzheimer's disease


Bipolar disorders



Cardiovascular management

Cardiovascular prevention

Cartilage repair

Chronic disorders prevention

Chronic heart failure

Clostridium difficile


Colorectal cancer




Emergency contraception

Erectile dysfunction


GBS for intrapartum maternity patients

gestational diabetes mellitus

Hand hygiene program

Heart failure

Hepatitis C



Infectious disorders

Leg ulcers


Lung transplantation

Medical Tourism

Medication distribution system


Myocardial infarction prevention


Nosocomial infections



Physical activity



Prevention of C-sections


Pulmonary hypertension


Renal Transplantation

Rheumatoid arthritis


Severe infections

Sleep disorders



Upper body disablement

Urinary tract infections

Virtual surgery simulation

Types of projects

Burden of illness study

Delphi panel

disease management program

Economic clinico-economic model

Economic piggyback trial

Economic Risk management trial

Literature review

Patient management program

Phase IV

Pilot project

Prospective trial


Retrospective trial

Time and motion study

Willingness to pay


  • 4 études de l'iedm
  • ASPQ
  • Article dans La Presse
  • JACO
  • Communiqué de presse FKQ
  • Livre Thérapeutiquepsychiatrique
  • ABCs of pharmacoeconomics : A reference guide
    • If you wish to receive a copy, please send us a message at: info@data4actions.com


Contact us

Julie Frappier, B.Sc. & M. Sc. Economics
Health economist

7 rue de Roncolo
Blainville, Québec, Canada
J7B 1Y7